# Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

> **NCT06384820** · PHASE2 · WITHDRAWN · sponsor: **Regeneron Pharmaceuticals**

## Conditions studied

- Cutaneous Squamous Cell Carcinoma

## Interventions

- **DRUG:** cemiplimab
- **DRUG:** fianlimab

## Key facts

- **NCT ID:** NCT06384820
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-11-14
- **Primary completion:** 2026-06-08
- **Final completion:** 2030-05-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2024-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06384820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06384820, "Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06384820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*